

MEDICINES CO /DE
Form 8-K
January 20, 2006

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): **January 16, 2006**

The Medicines Company

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

000-31191
(Commission
File Number)

04-3324394
(IRS Employer
Identification No.)

8 Campus Drive
Parsippany, New Jersey
(Address of Principal Executive Offices)

07054
(Zip Code)

Registrant's telephone number, including area code: **(973) 656-1616**

(Former Name or Former Address, if Changed Since Last Report)

Edgar Filing: MEDICINES CO /DE - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 1.01. Entry into a Material Definitive Agreement

On January 16, 2006, the Compensation Committee of the Board of Directors of The Medicines Company (the Company) approved 2005 annual cash bonus payments for the Company's executive officers in 2005. The Compensation Committee approved the bonus awards following an assessment of the Company's achievement of its goals for 2005 and the individual performance of each executive officer during 2005, in accordance with the Company's annual incentive plan. The following annual bonus payments were approved:

| 2005 Annual Bonus Payment | | |
|--|----|---------|
| Clive A. Meanwell Chief Executive Officer | \$ | 200,000 |
| John P. Kelley President and Chief Operating Officer | \$ | 120,000 |
| Steven H. Koehler Senior Vice President and Chief Financial Officer | \$ | 100,000 |
| John D. Richards Vice President | \$ | 60,996 |
| Paul M. Antinori Vice President and General Counsel | \$ | 80,000 |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE MEDICINES COMPANY

Date: January 20, 2006

By: /s/ Steven H. Koehler
Steven H. Koehler
Senior Vice President and Chief Financial Officer